Chapter/Section Purchase

1 Study Coverage
1.1 Acute Myeloid Leukemia Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 DC regimen
1.2.3 AVD Regimen
1.2.4 VCD regimen
1.3 Market by Application
1.3.1 Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Acute Myeloid Leukemia Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Acute Myeloid Leukemia Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Acute Myeloid Leukemia Drugs Sales by Region
2.4.1 Global Acute Myeloid Leukemia Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Acute Myeloid Leukemia Drugs by Region (2023-2028)
2.5 Global Acute Myeloid Leukemia Drugs Revenue by Region
2.5.1 Global Acute Myeloid Leukemia Drugs Revenue by Region (2017-2022)
2.5.2 Global Acute Myeloid Leukemia Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Acute Myeloid Leukemia Drugs Sales by Manufacturers
3.1.1 Global Top Acute Myeloid Leukemia Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Acute Myeloid Leukemia Drugs in 2021
3.2 Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers
3.2.1 Global Acute Myeloid Leukemia Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia Drugs Revenue in 2021
3.3 Global Acute Myeloid Leukemia Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Acute Myeloid Leukemia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Acute Myeloid Leukemia Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Acute Myeloid Leukemia Drugs Sales by Type
4.1.1 Global Acute Myeloid Leukemia Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Acute Myeloid Leukemia Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2017-2028)
4.2 Global Acute Myeloid Leukemia Drugs Revenue by Type
4.2.1 Global Acute Myeloid Leukemia Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Acute Myeloid Leukemia Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Acute Myeloid Leukemia Drugs Price by Type
4.3.1 Global Acute Myeloid Leukemia Drugs Price by Type (2017-2022)
4.3.2 Global Acute Myeloid Leukemia Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Acute Myeloid Leukemia Drugs Sales by Application
5.1.1 Global Acute Myeloid Leukemia Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Acute Myeloid Leukemia Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
5.2 Global Acute Myeloid Leukemia Drugs Revenue by Application
5.2.1 Global Acute Myeloid Leukemia Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Acute Myeloid Leukemia Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Acute Myeloid Leukemia Drugs Price by Application
5.3.1 Global Acute Myeloid Leukemia Drugs Price by Application (2017-2022)
5.3.2 Global Acute Myeloid Leukemia Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Acute Myeloid Leukemia Drugs Market Size by Type
6.1.1 North America Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
6.1.2 North America Acute Myeloid Leukemia Drugs Revenue by Type (2017-2028)
6.2 North America Acute Myeloid Leukemia Drugs Market Size by Application
6.2.1 North America Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
6.2.2 North America Acute Myeloid Leukemia Drugs Revenue by Application (2017-2028)
6.3 North America Acute Myeloid Leukemia Drugs Market Size by Country
6.3.1 North America Acute Myeloid Leukemia Drugs Sales by Country (2017-2028)
6.3.2 North America Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
6.3.3 the United States
6.3.4 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia Drugs Market Size by Type
7.1.1 Europe Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
7.1.2 Europe Acute Myeloid Leukemia Drugs Revenue by Type (2017-2028)
7.2 Europe Acute Myeloid Leukemia Drugs Market Size by Application
7.2.1 Europe Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
7.2.2 Europe Acute Myeloid Leukemia Drugs Revenue by Application (2017-2028)
7.3 Europe Acute Myeloid Leukemia Drugs Market Size by Country
7.3.1 Europe Acute Myeloid Leukemia Drugs Sales by Country (2017-2028)
7.3.2 Europe Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 UK
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Acute Myeloid Leukemia Drugs Market Size by Type
8.1.1 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Acute Myeloid Leukemia Drugs Market Size by Application
8.2.1 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Acute Myeloid Leukemia Drugs Market Size by Region
8.3.1 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia Drugs Market Size by Type
9.1.1 Latin America Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
9.1.2 Latin America Acute Myeloid Leukemia Drugs Revenue by Type (2017-2028)
9.2 Latin America Acute Myeloid Leukemia Drugs Market Size by Application
9.2.1 Latin America Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
9.2.2 Latin America Acute Myeloid Leukemia Drugs Revenue by Application (2017-2028)
9.3 Latin America Acute Myeloid Leukemia Drugs Market Size by Country
9.3.1 Latin America Acute Myeloid Leukemia Drugs Sales by Country (2017-2028)
9.3.2 Latin America Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Acute Myeloid Leukemia Drugs Market Size by Type
10.1.1 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Acute Myeloid Leukemia Drugs Market Size by Application
10.2.1 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Acute Myeloid Leukemia Drugs Market Size by Country
10.3.1 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Ambit Biosciences Corporation
11.1.1 Ambit Biosciences Corporation Corporation Information
11.1.2 Ambit Biosciences Corporation Overview
11.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Ambit Biosciences Corporation Recent Developments
11.2 Celgene Corporation
11.2.1 Celgene Corporation Corporation Information
11.2.2 Celgene Corporation Overview
11.2.3 Celgene Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Celgene Corporation Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Celgene Corporation Recent Developments
11.3 Cephalon
11.3.1 Cephalon Corporation Information
11.3.2 Cephalon Overview
11.3.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Cephalon Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cephalon Recent Developments
11.4 Clavis Pharma
11.4.1 Clavis Pharma Corporation Information
11.4.2 Clavis Pharma Overview
11.4.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Clavis Pharma Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Clavis Pharma Recent Developments
11.5 Eisai
11.5.1 Eisai Corporation Information
11.5.2 Eisai Overview
11.5.3 Eisai Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Eisai Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eisai Recent Developments
11.6 Genzyme Corporation
11.6.1 Genzyme Corporation Corporation Information
11.6.2 Genzyme Corporation Overview
11.6.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Genzyme Corporation Recent Developments
11.7 Sunesis Pharmaceuticals
11.7.1 Sunesis Pharmaceuticals Corporation Information
11.7.2 Sunesis Pharmaceuticals Overview
11.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sunesis Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Acute Myeloid Leukemia Drugs Industry Chain Analysis
12.2 Acute Myeloid Leukemia Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Acute Myeloid Leukemia Drugs Production Mode & Process
12.4 Acute Myeloid Leukemia Drugs Sales and Marketing
12.4.1 Acute Myeloid Leukemia Drugs Sales Channels
12.4.2 Acute Myeloid Leukemia Drugs Distributors
12.5 Acute Myeloid Leukemia Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Acute Myeloid Leukemia Drugs Industry Trends
13.2 Acute Myeloid Leukemia Drugs Market Drivers
13.3 Acute Myeloid Leukemia Drugs Market Challenges
13.4 Acute Myeloid Leukemia Drugs Market Restraints
14 Key Findings in The Global Acute Myeloid Leukemia Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer